 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase or [0m
[34mdecrease the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase the risk of gastrointestinal ulcer hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ALENDRONATE SODIUM increase the [0m
[32mrisk of gastrointestinal ulcer hospitalization?[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ALENDRONATE SODIUM increase the risk of gastrointestinal ulcer hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ALENDRONATE SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m5[0m[31m WARNINGS AND PRECAUTIONS Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue if new [0m
[31mor worsening symptoms occur. [0m[1;31m([0m[31m [0m[1;31m5.1[0m[31m [0m[1;31m)[0m[31m Hypocalcemia can worsen and must be corrected prior to use. [0m[1;31m([0m[31m [0m[1;31m5.2[0m[31m [0m[1;31m)[0m[31m Severe Bone, Joint, Muscle Pain may occur. Discontinue use if severe symptoms develop. [0m[1;31m([0m[31m [0m[1;31m5.3[0m[31m [0m[1;31m)[0m[31m [0m
[31mOsteonecrosis of the Jaw has been reported. [0m[1;31m([0m[31m [0m[1;31m5.4[0m[31m [0m[1;31m)[0m[31m Atypical Femur Fractures have been reported. Patients with new thigh or groin pain should be evaluated to rule out a femoral fracture. [0m[1;31m([0m[31m [0m[1;31m5.5[0m[31m [0m[1;31m)[0m[31m [0m
[31mSodium Content: Each tablet contains [0m[1;31m603[0m[31m mg sodium, equivalent to [0m[1;31m1532[0m[31m mg NaCl. Use caution in patients on sodium restriction. [0m[1;31m([0m[31m [0m[1;31m5.7[0m[31m [0m[1;31m)[0m[31m [0m[1;31m5[0m[31m. ALENDRONATE SODIUM: warnings_and_cautions: [0m[1;31m1[0m[31m Upper [0m
[31mGastrointestinal Adverse Reactions BINOSTO, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects [0m
[31mand a potential for worsening of the underlying disease, caution should be used when BINOSTO is given to patients with active upper gastrointestinal problems [0m[1;31m([0m[31msuch as known Barrett's esophagus, [0m
[31mdysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers[0m[1;31m)[0m[31m. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and [0m
[31mrarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates including alendronate sodium. In some cases these have been severe [0m
[31mand required hospitalization. ALENDRONATE SODIUM: warnings_and_cautions: Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be [0m
[31minstructed to discontinue BINOSTO and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. The risk of severe esophageal adverse experiences [0m
[31mappears to be greater in patients who lie down after taking oral bisphosphonates including alendronate sodium, and/or who continue to take oral bisphosphonates including alendronate sodium after [0m
[31mdeveloping symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [0m[31m . In patients who cannot [0m
[31mcomply with dosing instructions due to mental disability, therapy with BINOSTO should be used under appropriate supervision. ALENDRONATE SODIUM: warnings_and_cautions: There have been post-marketing [0m
[31mreports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials [0m[31m . [0m[1;31m5.2[0m[31m Mineral Metabolism[0m
[31mHypocalcemia must be corrected before initiating therapy with BINOSTO [0m[31m. Other disorders affecting mineral metabolism [0m[1;31m([0m[31msuch as vitamin D deficiency[0m[1;31m)[0m[31m should also be effectively treated. In patients with[0m
[31mthese conditions, serum calcium and symptoms of hypocalcemia should be monitored during therapy with BINOSTO. Presumably due to the effects of BINOSTO on increasing bone mineral, small, asymptomatic [0m
[31mdecreases in serum calcium and phosphate may occur. Patients should receive adequate calcium and vitamin D intake. [0m[1;31m5[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: overdosage: [0m[1;31m10[0m[31m OVERDOSAGE Significant lethality after single oral doses was seen in female rats and mice at [0m[1;31m552[0m[31m mg/kg [0m[1;31m([0m[1;31m3256[0m[31m mg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m and [0m[1;31m966[0m[31m mg/kg [0m[1;31m([0m[1;31m2898[0m[31m mg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m, [0m
[31mrespectively. In males, these values were slightly higher, [0m[1;31m626[0m[31m and [0m[1;31m1280[0m[31m mg/kg, respectively. There was no lethality in dogs at oral doses up to [0m[1;31m200[0m[31m mg/kg [0m[1;31m([0m[1;31m4000[0m[31m mg/m [0m[1;31m2[0m[31m [0m[1;31m)[0m[31m. No specific information is [0m
[31mavailable on the treatment of overdosage with BINOSTO. Hypocalcemia, hypophosphatemia, and upper gastrointestinal adverse events, such as upset stomach, heartburn, esophagitis, gastritis, or ulcer, [0m
[31mmay result from oral overdosage. Milk or antacids should be given to bind alendronate. Due to the risk of esophageal irritation, vomiting should not be induced and the patient should remain fully [0m
[31mupright. Dialysis would not be beneficial.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m


[31mCONTENT: ALENDRONATE SODIUM: adverse_reactions: The percentage of patients who discontinued the study due to any clinical adverse event was [0m[1;31m9.5[0m[31m% in the placebo group and [0m[1;31m8.9[0m[31m% in the alendronate group.[0m
[31mAdverse reactions from these studies considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to [0m[1;31m1[0m[31m% of patients treated with either alendronate or [0m
[31mplacebo are presented in Table [0m[1;31m1[0m[31m. ALENDRONATE SODIUM: adverse_reactions: Table [0m[1;31m1[0m[31m Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely [0m
[31mDrug Related by the Investigators and Reported in Greater Than or Equal to [0m[1;31m1[0m[31m% of Patients United States/Multinational Studies Fracture Intervention Trial Alendronate Sodium [0m[1;31m10[0m[31m mg/day for three years [0m
[31mPlacebo Alendronate Sodium [0m[1;31m5[0m[31m mg/day for [0m[1;31m2[0m[31m years and [0m[1;31m10[0m[31m mg/day for either [0m[1;31m1[0m[31m or [0m[1;31m2[0m[31m additional years Placebo % [0m[1;31m([0m[31mN = [0m[1;31m196[0m[1;31m)[0m[31m % [0m[1;31m([0m[31mN = [0m[1;31m397[0m[1;31m)[0m[31m % [0m[1;31m([0m[31mN = [0m[1;31m3236[0m[1;31m)[0m[31m % [0m[1;31m([0m[31mN = [0m[1;31m3223[0m[1;31m)[0m[31m Gastrointestinal Abdominal pain [0m[1;31m6.6[0m[31m [0m[1;31m4.8[0m[31m [0m[1;31m1.5[0m[31m [0m
[1;31m1.5[0m[31m Nausea [0m[1;31m3.6[0m[31m [0m[1;31m4.0[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m1.5[0m[31m Dyspepsia [0m[1;31m3.6[0m[31m [0m[1;31m3.5[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m1.2[0m[31m Constipation [0m[1;31m3[0m[31m. ALENDRONATE SODIUM: adverse_reactions: [0m[1;31m1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.2[0m[31m Diarrhea [0m[1;31m3.1[0m[31m [0m[1;31m1.8[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.3[0m[31m Flatulence [0m[1;31m2.6[0m[31m [0m[1;31m0.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m Acid regurgitation [0m[1;31m2.0[0m[31m [0m[1;31m4.3[0m
[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m Esophageal ulcer [0m[1;31m1.5[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Vomiting [0m[1;31m1.0[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.3[0m[31m Dysphagia [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.1[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m[1;31m0.8[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Gastritis [0m[1;31m0.5[0m[31m [0m[1;31m1.3[0m[31m [0m[1;31m0.6[0m[31m [0m[1;31m0.7[0m[31m Musculoskeletal Musculoskeletal [0m[1;31m([0m[31mbone, muscle[0m
[31mor joint[0m[1;31m)[0m[31m pain [0m[1;31m4.1[0m[31m [0m[1;31m2.5[0m[31m [0m[1;31m0.4[0m[31m [0m[1;31m0[0m[31m. ALENDRONATE SODIUM: adverse_reactions: [0m[1;31m3[0m[31m Muscle cramp [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.1[0m[31m Nervous system/psychiatric Headache [0m[1;31m2.6[0m[31m [0m[1;31m1.5[0m[31m [0m[1;31m0.2[0m[31m [0m[1;31m0.2[0m[31m Dizziness [0m[1;31m0.0[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.1[0m[31m Special senses Taste [0m
[31mperversion [0m[1;31m0.5[0m[31m [0m[1;31m1.0[0m[31m [0m[1;31m0.1[0m[31m [0m[1;31m0.0[0m[31m Rarely, rash and erythema have occurred. Gastrointestinal Adverse Reactions: One patient treated with alendronate sodium [0m[1;31m([0m[1;31m10[0m[31m mg/day[0m[1;31m)[0m[31m, who had a history of peptic ulcer [0m
[31mdisease and gastrectomy and who was taking concomitant aspirin developed an anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and alendronate sodium were discontinued [0m
[31mand the patient recovered. ALENDRONATE SODIUM: adverse_reactions: In the Study [0m[1;31m1[0m[31m and Study [0m[1;31m2[0m[31m populations, [0m[1;31m49[0m[31m-[0m[1;31m54[0m[31m% had a history of gastrointestinal disorders at baseline and [0m[1;31m54[0m[31m-[0m[1;31m89[0m[31m% used nonsteroidal [0m
[31manti-inflammatory drugs or aspirin at some time during the studies [0m[1;31m[[0m[31m see Warnings and Precautions [0m[1;31m([0m[1;31m5.1[0m[1;31m)[0m[31m [0m[1;31m][0m[31m. Laboratory Test Findings: In double-blind, multicenter, controlled studies, asymptomatic, [0m
[31mmild, and transient decreases in serum calcium and phosphate were observed in approximately [0m[1;31m18[0m[31m% and [0m[1;31m10[0m[31m%, respectively, of patients taking alendronate versus approximately [0m[1;31m12[0m[31m% and [0m[1;31m3[0m[31m% of those taking [0m
[31mplacebo. However, the incidences of decreases in serum calcium to less than [0m[1;31m8.0[0m[31m mg/dL [0m[1;31m([0m[1;31m2.0[0m[31m mM[0m[1;31m)[0m[31m and serum phosphate to less than or equal to [0m[1;31m2.0[0m[31m mg/dL [0m[1;31m([0m[1;31m0.65[0m[31m mM[0m[1;31m)[0m[31m were similar in both treatment groups. [0m
[31mALENDRONATE SODIUM: adverse_reactions: Weekly Dosing The safety of alendronate sodium [0m[1;31m70[0m[31m mg once weekly for the treatment of postmenopausal osteoporosis was assessed in a one-year, double-blind, [0m
[31mmulticenter study comparing alendronate [0m[1;31m70[0m[31m mg once weekly and alendronate [0m[1;31m10[0m[31m mg daily. The overall safety and tolerability profiles of once weekly alendronate [0m[1;31m70[0m[31m mg and alendronate [0m[1;31m10[0m[31m mg daily were [0m
[31msimilar. The adverse reactions considered by the investigators as possibly, probably, or definitely drug related in greater than or equal to [0m[1;31m1[0m[31m% of patients in either treatment group are presented in [0m
[31mTable [0m[1;31m2[0m[31m. ALENDRONATE SODIUM: adverse_reactions: Table [0m[1;31m2[0m[31m Osteoporosis Treatment Studies in Postmenopausal Women Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the [0m
[31mInvestigators and Reported in Greater Than or Equal to [0m[1;31m1[0m[31m% of Patients Once Weekly Alendronate Sodium [0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m519[0m[1;31m)[0m[31m Once Daily Alendronate Sodium [0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m370[0m[1;31m)[0m[31m Gastrointestinal Abdominal pain [0m
[1;31m3.7[0m[31m [0m[1;31m3.0[0m[31m Dyspepsia [0m[1;31m2.7[0m[31m [0m[1;31m2.2[0m[31m Acid regurgitation [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Nausea [0m[1;31m1.9[0m[31m [0m[1;31m2.4[0m[31m Abdominal distention [0m[1;31m1.0[0m[31m [0m[1;31m1.4[0m[31m Constipation [0m[1;31m0.8[0m[31m [0m[1;31m1.6[0m[31m Flatulence [0m[1;31m0.4[0m[31m [0m[1;31m1.6[0m[31m Gastritis [0m[1;31m0.2[0m[31m [0m[1;31m1.1[0m[31m Gastric ulcer [0m[1;31m0.0[0m[31m [0m[1;31m1[0m[31m. ALENDRONATE SODIUM: [0m
[31madverse_reactions: [0m[1;31m1[0m[31m Musculoskeletal Musculoskeletal [0m[1;31m([0m[31mbone, muscle, joint[0m[1;31m)[0m[31m pain [0m[1;31m2.9[0m[31m [0m[1;31m3.2[0m[31m Muscle cramp [0m[1;31m0.2[0m[31m [0m[1;31m1.1[0m[31m Osteoporosis in Men In two placebo-controlled, double-blind, multicenter studies in men [0m[1;31m([0m[31ma [0m
[31mtwo-year study of alendronate sodium [0m[1;31m10[0m[31m mg/day and a one-year study of once weekly alendronate sodium [0m[1;31m70[0m[31m mg[0m[1;31m)[0m[31m the rates of discontinuation of therapy due to any clinical adverse event were [0m[1;31m2.7[0m[31m% for [0m
[31malendronate [0m[1;31m10[0m[31m mg/day vs. [0m[1;31m10.5[0m[31m% for placebo, and [0m[1;31m6.4[0m[31m% for once weekly alendronate [0m[1;31m70[0m[31m mg vs. [0m[1;31m8.6[0m[31m% for placebo. The adverse reactions considered by the investigators as possibly, probably, or definitely[0m
[31mdrug related in greater than or equal to [0m[1;31m2[0m[31m% of patients treated with either alendronate or placebo are presented in the following table. ALENDRONATE SODIUM: adverse_reactions: Table [0m[1;31m3[0m[31m Osteoporosis [0m
[31mStudies in Men Adverse Reactions Considered Possibly, Probably, or Definitely Drug Related by the Investigators and Reported in Greater Than or Equal to [0m[1;31m2[0m[31m% of Patients Two-Year Study One-Year Study [0m
[31mOnce Daily Alendronate Sodium Once Weekly Alendronate Sodium [0m[1;31m10[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m146[0m[1;31m)[0m[31m Placebo % [0m[1;31m([0m[31mN = [0m[1;31m95[0m[1;31m)[0m[31m [0m[1;31m70[0m[31m mg % [0m[1;31m([0m[31mN = [0m[1;31m109[0m[1;31m)[0m[31m Placebo % [0m[1;31m([0m[31mN = [0m[1;31m58[0m[1;31m)[0m[31m Gastrointestinal Acid regurgitation [0m[1;31m4.1[0m[31m [0m[1;31m3.2[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Flatulence [0m
[1;31m4.1[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m Gastroesophageal reflux disease [0m[1;31m0.7[0m[31m [0m[1;31m3.2[0m[31m [0m[1;31m2.8[0m[31m [0m[1;31m0.0[0m[31m Dyspepsia [0m[1;31m3.4[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m2.8[0m[31m [0m[1;31m1.7[0m[31m Diarrhea [0m[1;31m1.4[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m2.8[0m[31m [0m[1;31m0[0m[31m. ALENDRONATE SODIUM: adverse_reactions: [0m[1;31m0[0m[31m Abdominal pain [0m[1;31m2.1[0m[31m [0m[1;31m1.1[0m[31m [0m[1;31m0.9[0m[31m [0m[1;31m3.4[0m[31m Nausea [0m[1;31m2.1[0m[31m [0m[1;31m0.0[0m
[1;31m0.0[0m[31m [0m[1;31m0.0[0m[31m [0m[1;31m6.2[0m[31m Post-Marketing Experience The following adverse reactions have been identified during post-approval use of alendronate sodium. Because these reactions are reported voluntarily from a [0m
[31mpopulation of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as a Whole : hypersensitivity reactions including[0m
[31murticaria and angioedema. Transient symptoms of myalgia, malaise, asthenia and fever have been reported with alendronate, typically in association with initiation of treatment. Symptomatic [0m
[31mhypocalcemia has occurred, generally in association with predisposing conditions. Peripheral edema. ALENDRONATE SODIUM: adverse_reactions: Gastrointestinal : esophagitis, esophageal erosions, [0m
[31mesophageal ulcers, esophageal stricture or perforation, and oropharyngeal ulceration. Gastric or duodenal ulcers, some severe and with complications have also been reported [0m[31m . Dental : Localized [0m
[31mosteonecrosis of the jaw, generally associated with tooth extraction and/or local infection with delayed healing, has been reported [0m[31m . Musculoskeletal : bone, joint, and/or muscle pain, occasionally [0m
[31msevere and incapacitating [0m[31m ; joint swelling; low-energy femoral shaft and subtrochanteric fractures [0m[31m . Nervous system : dizziness and vertigo. ALENDRONATE SODIUM: adverse_reactions: Pulmonary: acute [0m
[31masthma exacerbations Skin : rash [0m[1;31m([0m[31moccasionally with photosensitivity[0m[1;31m)[0m[31m, pruritus, alopecia, severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Special Senses : [0m
[31muveitis, scleritis or episcleritis. Cholesteatoma of the external auditory canal [0m[1;31m([0m[31mfocal osteonecrosis[0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:A[0m[31mLENDRONATE SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Alendronate sodium, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Esophageal adverse experiences such as esophagitis, [0m
[32mesophageal ulcers, and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with alendronate [0m
[32msodium. In some cases, these have been severe and required hospitalization. There have also been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and [0m
[32mwith complications, although no increased risk was observed in controlled clinical trials.[0m

[32mSOURCE: ALENDRONATE SODIUM label[0m
[32mEXTRACT_START_END: [0m[32m...[0m[32mesophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by[0m[32m...[0m[32mhospitalization.[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Alendronate sodium, like other [0m
[34mbisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Esophageal adverse experiences such as esophagitis, esophageal ulcers, and esophageal erosions, [0m
[34moccasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with alendronate sodium. In some cases, these have been severe[0m
[34mand required hospitalization. There have also been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk [0m
[34mwas observed in controlled clinical trials.[0m

[34mSOURCE: ALENDRONATE SODIUM label[0m
[34mEXTRACT_START_END: [0m[34m...[0m[34mesophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by[0m[34m...[0m[34mhospitalization.[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ALENDRONATE SODIUM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if ALENDRONATE SODIUM increases the risk of gastrointestinal ulcer hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that Alendronate sodium may cause local irritation of the upper gastrointestinal mucosa and has been associated with esophageal adverse experiences such as esophagitis, [0m
[32mesophageal ulcers, and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, which have required hospitalization. There have also been [0m
[32mpost-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ALENDRONATE SODIUM has been associated with gastrointestinal adverse effects that can be severe and may lead to hospitalization, such as esophageal ulcers and erosions. However, it is [0m
[32mimportant to note that while there have been post-marketing reports of severe gastric and duodenal ulcers with complications, no increased risk of gastrointestinal ulcer hospitalization was observed [0m
[32min controlled clinical trials. Therefore, while there is a potential risk, the degree of reliability of this association is not fully established, and the risk of hospitalization due to [0m
[32mgastrointestinal ulcers appears to be rare."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ALENDRONATE SODIUM increase or decrease the risk of gastrointestinal ulcer hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if ALENDRONATE SODIUM increases the risk of gastrointestinal ulcer hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that Alendronate sodium may cause local irritation of the upper gastrointestinal mucosa and has been associated with esophageal adverse experiences such as esophagitis, [0m
[34mesophageal ulcers, and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, which have required hospitalization. There have also been [0m
[34mpost-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ALENDRONATE SODIUM has been associated with gastrointestinal adverse effects that can be severe and may lead to hospitalization, such as esophageal ulcers and erosions. However, it is [0m
[34mimportant to note that while there have been post-marketing reports of severe gastric and duodenal ulcers with complications, no increased risk of gastrointestinal ulcer hospitalization was observed [0m
[34min controlled clinical trials. Therefore, while there is a potential risk, the degree of reliability of this association is not fully established, and the risk of hospitalization due to [0m
[34mgastrointestinal ulcers appears to be rare."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ALENDRONATE SODIUM increase or decrease the risk of gastrointestinal ulcer hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if ALENDRONATE SODIUM increases the risk of gastrointestinal ulcer hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that Alendronate sodium may cause local irritation of the upper gastrointestinal mucosa and has been associated with esophageal adverse experiences such as esophagitis, [0m
[31mesophageal ulcers, and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, which have required hospitalization. There have also been [0m
[31mpost-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials.[0m
[31m        -----[0m
[31m        Final answer: ALENDRONATE SODIUM has been associated with gastrointestinal adverse effects that can be severe and may lead to hospitalization, such as esophageal ulcers and erosions. However, [0m
[31mit is important to note that while there have been post-marketing reports of severe gastric and duodenal ulcers with complications, no increased risk of gastrointestinal ulcer hospitalization was [0m
[31mobserved in controlled clinical trials. Therefore, while there is a potential risk, the degree of reliability of this association is not fully established, and the risk of hospitalization due to [0m
[31mgastrointestinal ulcers appears to be rare.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge about the potential gastrointestinal side effects of alendronate [0m
[32msodium. The answer appropriately reflects the strength of evidence and the magnitude of the effect, acknowledging both the post-marketing reports and the controlled clinical trial data. There are no [0m
[32midentifiable flaws in the reasoning process."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge about the potential gastrointestinal side effects of alendronate [0m
[34msodium. The answer appropriately reflects the strength of evidence and the magnitude of the effect, acknowledging both the post-marketing reports and the controlled clinical trial data. There are no [0m
[34midentifiable flaws in the reasoning process."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is consistent with the information given by FDAHandler and aligns with medical knowledge about the potential gastrointestinal side effects of alendronate [0m
[31msodium. The answer appropriately reflects the strength of evidence and the magnitude of the effect, acknowledging both the post-marketing reports and the controlled clinical trial data. There are no [0m
[31midentifiable flaws in the reasoning process.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-gastrointestinal ulcer hospitalization-ALENDRONATE SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mALENDRONATE SODIUM has been associated with gastrointestinal adverse effects that can be severe and may lead to hospitalization, such as esophageal ulcers and erosions. However, it is important to [0m
[32mnote that while there have been post-marketing reports of severe gastric and duodenal ulcers with complications, no increased risk of gastrointestinal ulcer hospitalization was observed in controlled [0m
[32mclinical trials. Therefore, while there is a potential risk, the degree of reliability of this association is not fully established, and the risk of hospitalization due to gastrointestinal ulcers [0m
[32mappears to be rare.[0m
